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Abstract Warfarin is a commonly prescribed oral anti-
coagulant with narrow therapeutic index. It achieves anti-
coagulating effects by interfering with the vitamin K cycle.
Warfarin has two enantiomers, S(-) and R(?) and
undergoes stereoselective metabolism, with the S(-)
enantiomer being more effective. We reported the intra-
cellular metabolic proﬁle in HepG2 cells incubated with
S(-) and R(?) warfarin by GCMS. Chemometric method
PCA was applied to analyze the individual samples. A total
of 80 metabolites which belong to different categories were
identiﬁed. Two batches of experiments (with and without
the presence of vitamin K) were designed. In samples
incubated with S(-) and R(?) warfarin, glucuronic acid
showed signiﬁcantly decreased in cells incubated with
R(?) warfarin but not in those incubated with S(-)
warfarin. It may partially explain the lower bio-activity of
R(?) warfarin. And arachidonic acid showed increased in
cells incubated with S(-) warfarin but not in those incu-
bated with R(?) warfarin. In addition, a number of small
molecules involved in c-glutamyl cycle displayed ratio
variations. Intracellular glutathione detection further vali-
dated the results. Taken together, our ﬁndings provided
molecular evidence on a comprehensive metabolic proﬁle
on warfarin-cell interaction which may shed new lights on
future improvement of warfarin therapy.
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1 Introduction
Metabolomics is the systematic study of small-molecule
metabolite proﬁles in speciﬁc cellular processes (Daviss
2005). Small molecules, which belong to diverse categories
such as organic acids, amino acids, fatty acids, carbohy-
drates, nucleosides and the conjugates, ketones and alde-
hydes, are involved in biochemical processes and provide a
great deal of information on the status and functioning of a
living system. They might work together with certain
enzymes, or interact with other proteins or metabolites to
inﬂuence cellular pathways and form metabolic networ-
kings. Study of metabolite proﬁle directly reﬂects the
phenotypic alterations in response to genetic or environ-
ment changes, such as drug stimulations.
Warfarin is a commonly prescribed oral anticoagulant in
patients with prosthetic valve disease, venous thrombo-
embolism and stroke (Hirsh et al. 2001). This drug
decreases blood coagulation by inhibiting vitamin K cycle,
which is an essential process for the maturation of several
blood coagulating factors, including prothrombin and fac-
tor VII, IX, X. In the liver, vitamin K is ﬁrst reduced to its
hydroquinone, which acts as a mediator to activate the
enzyme c-glutamyl carboxylase (GGCX). Several coagu-
lating factors undergo vitamin K-dependent posttransla-
tional modiﬁcation by GGCX. Those Glutamic acid (Glu)
residues on those coagulating factors are modiﬁed into
c-carboxyglutamic acid (Gla), resulting in the maturation
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DOI 10.1007/s11306-010-0262-3of coagulating factors. Gla residue will mediate those
coagulating factors to bind to Ca
2? in the blood stream.
The binding is needed for activation of platelets as well as
other downstream coagulation factors and pathways
(Wu et al. 1991; Hirsh et al. 2001). Once completed the
c-carboxylation reaction, vitamin K hydroquinone is oxi-
dized to vitamin K epoxide form. Another enzyme, vitamin
K 2,3 epoxide reductase (VKOR), reduces vitamin K
epoxide to its reduced form, and the cycle repeats. War-
farin inhibits vitamin K cycle through interfering with
VKOR activity (Wajih et al. 2007; Tie and Stafford 2008),
thus inactivate the coagulation process.
Warfarin is a racemic drug consisting of S(-) and R(?)
enantiomers, with S(-) form being more effective (3–5
times) in vitro. However, this drug has a very wide thera-
peutic range and patients can be categorized into low-dose
and high-dose groups. Many factors have been proved to
affect warfarin dosage. Enantiomer drugs interaction with
body has been found to response for dosage variation to
some extent. Global study of cellular metabolic proﬁle
reveals the differences in biological responses between the
enantiomer drugs. The ﬁndings may contribute to the
improvement of warfarin therapy in terms of optimal
dosage as well as giving references to new coumarin-
derived drug development. To date, there are very few of
studies on cellular metabolite proﬁles which directly reﬂect
the biological responses from cells. Most investigations are
on drug metabolism and metabolites (Wsol et al. 2001;
Nassar et al. 2006; Wharfe et al. 2010). So far, a com-
parative study on complete metabolite proﬁles generated
from S(-) and R(?) enantiomers of warfarin hasn’t been
reported yet.
Mass spectrometry has occupied a major position in
determining the metabolic status, as it provides a better
way to identify metabolites effectively, both quantitative
and qualitative. Gas chromatography and mass spectrom-
etry (GC–MS) was applied in the metabolites identiﬁcation
in our study. This high resolution GC separation interfaces
with sensitive detection of MS is able to yield both quali-
tative and quantitative information on metabolites (Dunn
and Ellis 2005). Samples were chemical derivatized to be
more volatile before analysis and spectra generated were
analyzed by chemometric methods. The established meta-
bolomic patterns can be applied to investigate on S(-) and
R(?) warfarin cellular responses.
In this study, we used GC–MS to semi-quantify the
differences on metabolite levels between untreated human
liver cells and those incubated by S(-) and R(?) warfarin,
respectively. To better reﬂect in vivo condition, similar
analysis was also carried out in cells incubated with war-
farin in the presence of vitamin K. The results have clas-
siﬁed the generated metabolites and identiﬁed the changes,
respectively. The expressions of ten molecules including
glycine, 5-oxoproline in drug-incubated groups were
signiﬁcantly varied compared to control groups. Several
molecules including arachidonic acid and glucuronic acid
expressed differentially between S(-) and R(?) warfarin.
In addition, results from cellular glutathione assay further
supported our results.
2 Materials and methods
2.1 Cell cultures
HepG2 cells were purchased from American Type Culture
Collection and cultured in minimum essential medium
(MEM, supplemented with 10% FBS, penicillin (100 U/ml),
and streptomycin (100 U/ml)). All culture media and
media supplements were purchased from Life Technolo-
gies. Then cells were maintained at 37C in an atmo-
sphere of 5% CO2. After cell seeding and reaching 80%
conﬂuence (10 cm tissue culture dish), in the ﬁrst set, the
cells were incubated with either S(-)o rR( ?) warfa-
rin (commercially available in Sigma–Aldrich, Product
Num.:UC213 and UC 214) at a concentration of 20 lM,
respectively, for 24 h in the absence of serum. For the
second set, cells were supplied with physiological con-
centration of vitamin K (Sigma–Aldrich) (0.5 lM) for
12 h, then again 20 lM of either S(-)o rR ( ?) enantiomer
of warfarin was used to incubate the cells separately for
another 24 h, in the absence of FBS. To minimize the error,
before harvest, cells were washed by cold PBS for 3 times
and the numbers were counted and normalized. The same
amount of cells (10 million) for each sample was harvested
by trypsin in 15 ml plastic tubes by low-speed centrifu-
gation. To minimize the factors which may contribute to
metabolites’ instability and to maintain the integrity of
metabolite proﬁles, the cells were immediately stored in
liquid nitrogen before lysis.
2.2 Cell lysis, metabolite extraction and derivatization
Metabolites were extracted using mono-phasic mixture of
chloroform/methanol/water, according to the generic pro-
tocols described in previous articles (Atherton et al. 2006;
Mainak et al. 2009), with minor modiﬁcation. Basically,
1 ml of chloroform/methanol/water mixture in the ratio of
20:50:20 was added to each sample, in a chemical fume
hood since chloroform is a carcinogen. Then every sample
was transferred to individual 2 ml glass tubes, as chloro-
form may react with plastic. Next, cells with extraction
reagents were undergone ultra-sonication at room temper-
ature in a water bath sonicator for 100 min and votexed for
2 min. Subsequently, samples were transferred to 1.5 ml
centrifugation tubes and centrifuged at 4C at 180009g for
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12320 min. Then for each sample, 0.8 ml supernatant was
collected. The supernatant was dried completely by cen-
trifugal evaporator (Jouan) overnight.
For GC–MS analysis, a two-stage chemical derivatiza-
tion was performed on the extracted metabolites. Firstly,
methoxymation was conducted to convert enol forms of
aldehydes and ketones in the metabolites to oximes or
alkyloximes (Halket and Zaikin 2003). The dry samples
were each dissolved in 100 ll of methoxylamine hydro-
chloride (20 mg/ml in pyridine, Sigma–Aldrich), and vot-
exed for 1 min, and incubated at room temperature for 1 h.
Secondly, silylation was performed by MSTFA (N-methyl-
N-(trimethylsilyl) triﬂuoroacetamide, Sigma–Aldrich) to
make the metabolites less polar and more volatile. Basi-
cally, 100ul MSTFA with 1% TMCS (Trimethylchlorosi-
lane, Sigma–Aldrich) was applied to each sample. Samples
were incubated at 70C for 30 min, and then transferred to
vials for GC–MS analysis.
2.3 GC–MS analysis
The separation and detection of metabolites was per-
formed by a Shimadzu QP2010plus GC–MS system
(Shimadzu, Kyoto, Japan), with a 30 m 9 0.25 mm i.d.
DB5 capillary column (122-5033 Agilent Technologies),
in the splitless mode. Each 1.0 ll aliquot of the deriva-
tized sample was injected by Shimadzu AOC-20i?s auto-
sampler (Shimadzu, Kyoto, Japan) and rinsed the needle
with acetone each ﬁve times for both pre- and post-run to
avoid sample cross-contamination. The solvent cutoff time
was set to 3.5 min. Helium was used as carrier gas with
the column ﬂow 1.1 ml/min. The injection temperature
was set to 280C and ion source temperature was set to
200C. The initial oven temperature was kept at 100C for
4 min, increased at 4C/min to 320C. At 320C, it held
for 1.56 min. The mode for mass spectrometry was elec-
tron impact (EI) ionization (70 eV) and data acquisition
was in the full scan mode (m/z from 35 to 600). Between
each sample, acetone was run as blank with the same
method to avoid cross-contamination. Before analysis,
standard alkane series mixture (C-10 to C-40) was used to
correct the retention time before analysis. This correction
was performed by AART (automatic adjustment of
Retention time) from Shimadzu GCMSsolution (version
2.5) software package.
2.4 Metabolites detection and quantiﬁcation
The total ion chromatogram and deconvolution was
acquired by Shimadzu GCMSsolution software package.
The chromatogram of all the samples analyzed was under
noise reduction and baseline correction before peak inte-
gration. Interesting peaks, with width at half-height being
more than 2 s, were selected and subjected to library
search. It is the standard to distinguish between noises and
peaks. Other parameters, such as automatic assignments of
unique fragment ions for each metabolite, and sensitivity of
peak detection, were built-in functions in the software.
In this study we used two libraries, National Institute of
Standards and Technology (NIST) Mass Spectra Library
and Shimadzu’s GC–MS Metabolite Mass Spectra Data-
base to search for candidate compounds. Peaks with simi-
larity index (SI) being more than 70% were selected and
named for the compounds. If more than one compounds
fulﬁlled the SI requirement, then Shimadzu’s GC–MS
Metabolite Mass Spectra Database equipped with retention
indices was used to give a more speciﬁc and reliable
identiﬁcation for candidate compounds. After data nor-
malization, the large amount of metabolite information was
analyzed with PCA by software SIMCA-P (version 12.0;
Umetrics, Umea ˚, Sweden). This method is an unsupervised
clustering method, which looks for linear combinations of
variables that explain those biggest differences between
individual samples. Relative quantiﬁcation of selected
compounds was performed by normalizing and comparing
the relative chromatograph peak areas.
2.5 Intracellular glutathione (GSH) detection
Glutathione (GSH) plays a central role in protecting cells
from free radical damages. It exists in two forms: reduced
form GSH and oxidized form GSSG. The decrease of
GSH/GSSG ratio reﬂects cellular ROS (Reactive Oxygen
Species) increasing. To determine the intracellular GSH
level and verify warfarin’s effect on c-glutamyl cycle,
ThiolTracker
TM Violet dye (Invitrogen) was applied. This
dye is a thiol reactive dye to label cells, and can be
efﬁciently excited for imaging with ﬂuorescence micro-
scopes. Basically, 2 9 10
4 HepG2 cells were seeded to
each well of 24-well plates. We still designed two sets of
experiment (without and with vitamin K) as described
above. When the cell reached 70% conﬂuence, for the ﬁrst
set, 20 lMo fS ( -) enantiomer, R(?)enantiomer of war-
farin were added, respectively, and incubated for 24 h. For
the second set, each well was incubated with 0.5 lM
vitamin K for 12 h, then again 20 lMo fS ( -) enantiomer,
R(?) enantiomer of warfarin were added and incubated
for another 24 h. Then media were removed and cells
were rinsed twice by PBS. 0.5 ml PBS with ﬁnal con-
centration 20 lM ThiolTracker Violet dye was applied to
incubate the cells in each vial at 37C for 30 min. Then
the dye was removed and replaced by PBS. Cells were
observed under ﬂuorescent microscope (Olympus). The
ThiolTracker Violet has excitation/emission maxima of
approximately 404/526 nm and can be observed by stan-
dard ﬂuorescent ﬁlter sets.
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To establish a comprehensive cellular metabolite proﬁle in
response to warfarin incubation, metabolites were extracted
from cells incubated with individual enantiomers of war-
farin and subjected to GC–MS analysis. The experiment
was performed with three independent times. Figure 1 was
a representative for the overlay of chromatography from
HepG2 incubated with Control and S(-)o rR ( ?) Warfarin.
A total of 80 metabolites were identiﬁed (Supplementary
material provided the list of the 80 metabolites, with their
names, retention times and categories). These metabolites
were separated into ten categories based on their chemical
compositions. These included amino acids, hydroxy acids,
carbohydrates, nucleosides and nucleoside conjugates, fatty
acids, alcohols, carboxylic acids, ketones, aldehydes and
other organic acids which do not belong to any catego-
ries above. The results indicated that a large number of
metabolites detected in both sets (with and without
vitamin K) were amino acids, hydroxyl acids, carbohy-
drates. It was shown that amino acids eluted ﬁrst, then
followed by carbohydrates (mainly monosaccharides), with
the fatty acids came last.
For those peaks detected, the peak area was calculated
and normalized using internal standard ribitol. Relative
quantiﬁcation assessment was performed by comparing the
peak areas of individual samples. Results were summa-
rized in Table 1 for cells incubated with the individual
enantiomers of warfarin, and for cells incubated with
the individual enantiomers of warfarin in the presence of
vitamin K.
A total of ten metabolites showed changes in their level
in Table 1. Most metabolites displayed similar changes
in cells incubated with either S(-)o rR ( ?) warfarin.
However, some of them showed changes to one but not all
enantiomers of warfarin.
For example, arachidonic acid, whose function is
involved in coagulation process, was up-regulated for
around 40% in cells incubated with S(-) warfarin but not
in those incubated with R(?) warfarin, while glucuronic
acid showed down-regulated in R(?) warfarin but not that
much in S(-) warfarin. In addition, glycine, 5-oxoproline,
L-glutamine, L-valine and L-threonine showed up-regulated
in both enantiomers with similar ratio; while L-serine,
L-glutamate and L-lactic acid showed down-regulated. The
other set (vitamin K enhanced) showed the same results.
Subsequently, PCA results provided more information
on multi-variables. Separation was according to the prin-
ciple components values on untreated, S(-) warfarin and
R(?) warfarin incubated samples. Each of the samples
Fig. 1 Overlay of representative GC/MS chromatography of HepG2 cells incubated by warfarin S(-) and R(?) enantiomers
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123incubated by control, S(-) warfarin and R(?) warfarin in
the three independent experiments was analyzed. The
results could be found in Fig. 2. In the score plot (Fig. 2,
Panel 1, a), different groups had been clearly separated
according to the scores. The further the distance in the plot
showed, the more different the samples were. It can be
concluded that S(-) warfarin has greater variance than
R(?) warfarin from the control group. In the loading plot
(Fig. 2, Panel 1, b), the relative peak areas of individual
metabolites contributed to the loading values. Those
metabolites with larger variation between drug-incubated
and non-incubated samples were dispensed further from the
origin. In addition, the results from vitamin K enhanced set
(Fig. 2, Panel 2, c and d), provided further validation.
Several amino acids, including glycine, 5-oxoproline,
L-glutamate were involved in glutathione (GSH) genera-
tion. To detected the intracellular glutathione level for the
validation of changes on above amino acids by S(-) and
R(?) warfarin, glutathione level was measured and results
were shown in Fig. 3, while a were the results for samples
incubated with warfarin alone and b are the results for
samples incubated with warfarin in the presence of vitamin
K. In the ﬁrst set, glutathione level showed increased in
S(-) and R(?) warfarin incubated samples, while the level
was increased more in HepG2 cells incubated by S(-)
warfarin than R(?) warfarin. In the second set, the gluta-
thione level was enhanced in the S(-) and R(?) warfarin,
which was consistent with the results from 1st set.
It indicated that warfarin enantiomers have effects on
enhancing the intracellular glutathione levels.
4 Discussion
4.1 Inﬂuence on c-glutamyl cycle and glutathione level
by warfarin
In our results, it has been shown that several amino acids
varied in their expression ratio. The elevated level of
glycine, L-glutamine, 5-oxoproline and decreased level
of L-glutamate may be associated with warfarin induced
glutathione production thus subsequently inﬂuenced
c-glutamyl cycle and hepatic c-glutamyl transferase. An
overall change in the cellular metabolic process by war-
farin was depicted in Fig. 4.
It has been reported that warfarin administration
increased both serum and hepatic c-glutamyltransferase
activity in rats (Lake and Grasso 1996). This protein
c-glutamyltransferase is a critical enzyme on c-glutamyl
cycle, which is a transport system for amino acids and
generation of glutathione (Orlowski and Meister 1970;
Meister 1974).
In c-glutamyl cycle, glutathione is broken down to
glycine, cysteine and glutamate. Four enzymes catalyze the
reaction. c-glutamyl transferase transfers c-glutamyl moi-
ety of glutathione to one amino acid, generation c-glutamyl
amino acid and cysteinylglycine. The cysteinylglycine is
split to glycine and cysteine. c-glutamyl cyclotransferase
converts c-glutamyl amino acid to 5-oxoproline and cor-
responding amino acid. Thus the process has transported
the amino acid transmembranely. After that, 5-oxoproline
is converted to glutamate by 5-oxoprolinase. The generated
Table 1 Metabolites identiﬁed whose expression ratio varied at least 10% in all three independent experiments, in the results without and
with Vitamin K pre-incubation
Name Retention time (min) Warfarin Warfarin ? Vitamin K
Ave S:C (SD) p (S:C) Ave R:C (SD) p (R:C) Ave S:V (SD) p (S:V) Ave R:V (SD) p (R:V)
L-lactic acid 10.04 0.76 ± 0.07 0.013 0.68 ± 0.18 0.045 0.67 ± 0.08 0.009 0.75 ± 0.07 0.0112
Glycine 14.38 1.56 ± 0.16 0.013 1.67 ± 0.03 3E-04 1.49 ± 0.09 0.005 1.51 ± 0.07 0.0029
L-valine 15.52 1.44 ± 0.05 0.002 1.31 ± 0.13 0.049 1.43 ± 0.04 0.001 1.30 ± 0.05 0.0043
L-serine 20.59 0.78 ± 0.03 0.002 0.86 ± 0.03 0.009 0.67 ± 0.07 0.006 0.75 ± 0.07 0.0131
L-threonine 21.47 1.15 ± 0.05 0.018 1.11 ± 0.07 0.055 1.19 ± 0.06 0.018 1.16 ± 0.10 0.0575
5-oxoproline 25.88 1.61 ± 0.10 0.005 1.32 ± 0.04 0.003 1.46 ± 0.06 0.003 1.45 ± 0.11 0.0093
L-glutamate 28.66 0.77 ± 0.06 0.011 0.74 ± 0.11 0.027 0.76 ± 0.04 0.004 0.75 ± 0.06 0.0092
L-glutamine 33.14 1.84 ± 0.06 9E-04 1.75 ± 0.08 0.002 1.73 ± 0.14 0.006 1.69 ± 0.17 0.013
Glucuronic lactone 34.34 0.91 ± 0.14 0.07 0.73 ± 0.02 0.032 0.87 ± 0.03 0.009 0.59 ± 0.08 0.0058
Arachidonic acid 47.12 1.40 ± 0.05 0.003 1.18 ± 0.07 0.025 1.41 ± 0.07 0.025 1.10 ± 0.07 0.1289
In the left panel, C control group, S S(-) warfarin incubated group, R R(?) warfarin incubated group. Ave S:C the average ratio of S(-) warfarin
incubated group compared to control group in the three times of the experiment, Ave R:C the average ratio of R(?) warfarin incubated group
compared to control group in the three times of the experiment. SD standard deviation of the three ratio; p(S:C)o rp(R:C) P values calculated
from Student’s t-test. In the right panel, V vitamin K treated group, S vitamin K incubated then S(-) warfarin incubated group, R vitamin K
incubated then R(?) warfarin incubated group. Ave S:V the average ratio of S(-) warfarin incubated group compared to vitamin K treated group
in the three times of the experiment; Ave R:V the average ratio of R(?) warfarin incubated group compared to vitamin K treated group in the
three times of the experiment. SD standard deviation of the three ratio; p(S:V)o rp(R:V) P values calculated from Student’s t-test
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123glutamate is combined with cysteine and glycine coming
from previous cysteinylglycine and the glutathione syn-
thetase to re-synthesize glutathione. Then the cycle repeats.
Glutathione is an antioxidant which helps protect cells
from reactive oxygen species (ROS). It exists in reduced
form (GSH) and oxidized disulﬁde form (GSSG), and a
decreased GSH-to-GSSG ratio is considered oxidative
stress generated by ROS. Warfarin increases the hepatic
total glutathione level that the increase is primarily due to
elevated GSH levels with very little effect on GSSG level
(Lake and Grasso 1996). The results may indicate a
decreased level of ROS generation on warfarin adminis-
tration. In our previous study on intracellular protein pro-
ﬁles generated by HepG2 cells incubated with warfarin
enantiomers, we have reported that protein DJ-1, which is a
protein marker for intracellular ROS, was down-regulated
in the cells incubated by warfarin (Bai et al. 2010). This
suggested a reduced level of intracellular ROS by warfarin,
which was consistent with our metabolic ﬁnding herein.
Glutathione is the substrate of Glutathione-S-tranferase
(GST). As it has been proposed that GST superfamily
contained a groups of warfarin-sensitive GST, which was
associated with Vitamin K Epoxide Reductase (VKOR)
and was a part of the trans-membrane enzyme (Cain et al.
1997). The outcome is: the elevation of glutathione may
also be due to the deduced VKOR complex activity by
warfarin. Thus affects c-glutamyl cycle with several
metabolites and hepatic c-glutamyl transferase.
Fig. 2 PCA results for relative
peak intensities between
different samples. Panel 1
a Score plot and b loading plot
for HepG2 cells incubated by
warfarin enantiomers only. In
the score plot, C1–C3 were cells
without any treatment; S1–S3
were cells incubated by S(-)
enantiomer of warfarin; R1–R3
were cells incubated by R(?)
enantiomer of warfarin. In the
loading plot, three PCs were
selected to represent a spatial
distribution of different
metabolites. Panel 2, c Score
plot and d loading plot for
HepG2 cells incubated by
warfarin enantiomers, in the
presence of vitamin K. In the
score plot, V1–V3 were cells
incubated by vitamin K only;
S1–S3 were cells incubated by
vitamin K then S(-) enantiomer
of warfarin; R1–R3 were cells
incubated by vitamin K then
R(?) enantiomer of warfarin. In
the loading plot, three PCs were
selected to represent a spatial
distribution of different
metabolites
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123In addition, as c-glutamyl cycle transports amino acids
transmembranely, the elevation or decrease of other intra-
cellular L-amino acid levels, such as L-valine, L-serine or
L-threonine may be attributed to the change of amino acid
transportation by c-glutamyl cycle.
4.2 Inﬂuence on uptake of vitamin K by warfarin
Another possible reason for elevated level of intracellular
glycine is: one function of glycine is to combine with
cholic acid and to form bile acid (Kevresan et al. 2006).
The binding will enhance the hepatic uptake of fat-soluble
vitamin K (Hollander and Rim 1976). In that case, increase
of unbound intracellular glycine may reﬂect the reduced
uptake of vitamin K.
4.3 Inﬂuence on glucuronidation by warfarin stereo-
selectivity
The next down-regulated metabolite is glucuronic lactone.
It is the stable form of glucuronic acid, as glucuronic acid
normally does not exist in free acid. Glucuronidation is a
process of glucuronic acid conjugated with xenobiotic
metabolism of substances such as drugs, to facility the
Fig. 2 continued
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123transport and elimination of those substances (Jansing et al.
1992; Ritter 2000). The conjugation involves glycosidic
bonds. It mainly occurs in the liver and is a part of
phase II metabolism of drugs. Until very recently, it has
been reported that glucuronidation could abolish the
binding between warfarin and its targeting enzyme,
VKOR, due to introduction of a bulky acidic sugar
(Miller et al. 2009). In our results, R(?) warfarin incu-
bated sample showed a more decreased level of this
metabolite, compared to S(-) warfarin. It consistent with
the previous ﬁnding that R(?) warfarin may be more
tended to be glucuronidated. The tendency of R(?)
Fig. 3 Intracellular glutathione
level of HepG2 cells incubated
with drugs. a glutathione level
of 1st set of experiment (without
vitamin K pre-incubation). The
left group was ﬂuorescent view
and the right group was
ﬂuorescent view with
corresponding light view.
b glutathione level of 2nd set of
experiment (with vitamin K pre-
incubation). The left group was
ﬂuorescent view and the right
group was ﬂuorescent view with
corresponding light view
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123warfarin may contribute to the lower biological activity
of this enantiomer.
4.4 Inﬂuence on arachidonic acid metabolism
by warfarin stereo-selectivity
Another elevated metabolite is arachidonic acid. It is a
polyunsaturated omega-6 fatty acid and presents in the
phospholipids of cell membranes. In addition, it is also
involved in cellular signaling (Baynes et al. 2005). War-
farin undergoes stereo-selective metabolism and S(-)
enantiomer are mainly metabolized by Cytochrome P450
2C9 (CYP2C9) and R(?) warfarin by CYP1A2 and
CYP3A4. In the previous study, it has been addressed that
CYP2C9 enzymes metabolize warfarin and arachidonic
acid (Kaur-Knudsen et al. 2009). Possibly, the presence of
S(-) warfarin enantiomer may affect the metabolism of
arachidonic acid. Arachidonic acid is the precursor for
synthesis thromboxane A2, which has prothrombotic
properties (Catella et al. 1986). This thromboxane A2
enhances the liver-generated ﬁbrinogen bindings to plate-
lets for activation (Al Mondhiry et al. 1983). Thus it does
not exclude the possibility that the presence of warfarin, by
regulating arachidonic metabolism, may indirectly affect
the coagulating process.
5 Concluding remarks
We reported the intracellular metabolic proﬁle in HepG2
cells incubated with S(-) and R(?) warfarin, using
GC–MS. Glucuronic acid, arachidonic acid showed varia-
tions on cells incubated with S(-) warfarin and R(?)
warfarin. For other metabolites like glycine, 5-oxoproline
and glutamate, the expressions each were found to be the
same in cells incubated with either S(-)o rR ( ?) warfarin.
Our results indicated that the expression of those metabo-
lites may partially explain the different bio-activities
Fig. 4 Over all changes in the cellular metabolic process by warfarin.
The expression of GST, which is associated with Vitamin K Epoxide
Reductase (VKOR) may be affected by warfarin incubation. The
expression of glutathione may also be affected by warfarin thus
inﬂuence c-glutamyl cycle with related metabolites such as glycine,
5-oxoproline and glutamate. This cycle is a transport system for
amino acids. Its regulation by warfarin may lead to increase of hepatic
c-glutamyl transferase activity. In addition, warfarin metabolism is
stereo-selective. Arachidonic acid and glucuronic acid are affected by
S(-) and R(?) warfarin, respectively. Expression ratio elevated
molecules were highlighted in red while reduced highlighted in blue.
An increased GSH-to-GSSG ratio is considered indicative of reduced
ROS. GGCX c-glutamyl carboxylase, VKOR vitamin K 2,3 epoxide
reductase, NQO1 NAD(P)H quinone oxidoreductase 1, GST: Gluta-
thione-S-tranferase, AA amino acid
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123between the two enantiomers and addressed that the cycle
for generation of glutathione may be interfered by warfarin.
Taken together, our ﬁndings provided molecular evidence
on a comprehensive metabolite proﬁle on warfarin-cell
interaction which may shed new lights on future
improvement of warfarin therapy.
Acknowledgments This work was supported by Grant NMRC/
EDG/0033/2008 (WN Chen). J Bai, MX Wang are recipients of
graduate research scholarship from Nanyang Technological Univer-
sity, Singapore.
Conﬂict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Al Mondhiry, H., Ballard, J. O., et al. (1983). Fibrinogen interaction
with human platelets: Effect of other coagulation factors,
prostaglandins and platelet inhibitors. Thrombosis Research,
31, 415–426.
Atherton, H. J., Bailey, N. J., et al. (2006). A combined 1H-NMR
spectroscopy- and mass spectrometry-based metabolomic study
of the PPAR ± null mutant mouse deﬁnes profound systemic
changes in metabolism linked to the metabolic syndrome.
Physiological Genomics, 27, 178–186.
Bai, J., Sadrolodabaee, L., et al. (2010). A comparative proteomic
analysis of HepG2 cells incubated by S(-) and R(?) enantio-
mers of anti-coagulating drug warfarin. Proteomics, 10,
1463–1473.
Baynes, J., et al. (2005). Medical biochemistry. Philadelphia: Elsevier.
Cain, D., Hutson, S. M., et al. (1997). Assembly of the warfarin-
sensitive vitamin K 2,3-epoxide reductase enzyme complex in
the endoplasmic reticulum membrane. Journal of Biological
Chemistry, 272, 29068–29075.
Catella, F., Healy, D., et al. (1986). 11-dehydrothromboxane B2:
A quantitative index of thromboxane A2 formation in the human
circulation. Proceedings of the National Academy of Sciences of
the United States of America, 83, 5861–5865.
Daviss, B. (2005). Growing pains for metabolomics. Scientist, 19,
25–28.
Dunn, W. B., & Ellis, D. I. (2005). Metabolomics: Current analytical
platforms and methodologies. TrAC Trends in Analytical
Chemistry, 24, 285–294.
Halket, J. M., & Zaikin, V. G. (2003). Derivatization in mass
spectrometry—1. Silylation. European Journal of Mass Spec-
trometry, 9, 1–21.
Hirsh, J., Dalen, J. E., et al. (2001). Oral anticoagulants: Mechanism
of action, clinical effectiveness, and optimal therapeutic range.
Chest, 119, 8S–21S.
Hollander, D., & Rim, E. (1976). Vitamin K2 absorption by rat
everted small intestinal sacs. American Journal of Physiology,
231, 415–419.
Jansing, R. L., Chao, E. S., et al. (1992). Phase II metabolism of
warfarin in primary culture of adult rat hepatocytes. Molecular
Pharmacology, 41, 209–215.
Kaur-Knudsen, D., Bojesen, S. E., et al. (2009). Common polymor-
phisms in CYP2C9, subclinical atherosclerosis and risk of
ischemic vascular disease in 52000 individuals. Pharmacoge-
nomics Journal, 9, 327–332.
Kevresan, S., Kuhajda, K., et al. (2006). Biosynthesis of bile acids in
mammalian liver. European Journal of Drug Metabolism and
Pharmacokinetics, 31, 145–156.
Lake, B. G., & Grasso, P. (1996). Comparison of the hepatotoxicity of
coumarin in the rat, mouse, and Syrian hamster: A dose and time
response study. Fundamental and Applied Toxicology, 34,
105–117.
Mainak, M., Koon, K. P., et al. (2009). Development and validation of
a gas chromatography/mass spectrometry method for the met-
abolic proﬁling of human colon tissue. Rapid Communications in
Mass Spectrometry, 23, 487–494.
Meister, A. (1974). The gamma glutamyl cycle. Diseases associated
with speciﬁc enzyme deﬁciencies. Annals of Internal Medicine,
81, 247–253.
Miller, G. P., Jones, D. R., et al. (2009). Assessing cytochrome P450
and UDP-glucuronosyltransferase contributions to warfarin
metabolism in humans. Chemical Research in Toxicology, 22,
1239–1245.
Nassar, A., Talaat, R. E., et al. (2006). The impact of recent
innovations in the use of liquid chromatography-mass spectrom-
etry in support of drug metabolism studies: Are we all the way
there yet? Current Opinion in Drug Discovery & Development,
9, 61–74.
Orlowski, M., & Meister, A. (1970). The gamma-glutamyl cycle:
A possible transport system for amino acids. Proceedings of the
National Academy of Sciences of the United States of America,
67, 1248–1255.
Ritter, J. K. (2000). Roles of glucuronidation and UDP-glucuronosyl-
transferases in xenobiotic bioactivation reactions. Chemico-
Biological Interactions, 129, 171–193.
Tie, J. K., & Stafford, D. W. (2008). Structure and function of vitamin
K epoxide reductase. Vitamin K (Vol. 78, pp. 103–130). San
Diego: Elsevier Academic Press Inc.
Wajih, N., Hutson, S. M., et al. (2007). Disulﬁde-dependent protein
folding is linked to operation of the vitamin K cycle in the
endoplasmic reticulum—a protein disulﬁde isomerase-VKORC1
redox enzyme complex appears to be responsible for vitamin
K-1 2,3-epoxide reduction. Journal of Biological Chemistry,
282, 2626–2635.
Wharfe, E. S., Winder, C. L., et al. (2010). Monitoring the effects of
chiral pharmaceuticals on aquatic microorganisms by metabolic
ﬁngerprinting. Applied and Environmental Microbiology, 76,
2075–2085.
Wsol, V., Kral, R., et al. (2001). Stereospeciﬁcity and stereoselec-
tivity of ﬂobufen metabolic proﬁle in mate rats in vitro and in
vivo: Phase I of biotransformation. Chirality, 13, 754–759.
Wu, S. M., Cheung, W. F., et al. (1991). Cloning and expression of
the cDNA for human gamma-glutamyl carboxylase. Science,
254, 1634–1636.
362 J. Bai et al.
123